Keyphrases
Calreticulin
100%
Immunogenic Cell Death
100%
Mouse Melanoma
100%
Therapeutic Approaches
66%
Surgical Resection
33%
Clinical Trials
33%
Malignancy
33%
Therapeutic Strategies
33%
Early Diagnosis
33%
Cell Membrane
33%
Increased Incidence
33%
Immune Response
33%
Autoimmune Disease
33%
Difficult-to-treat
33%
Human Malignancies
33%
Alternative Therapeutics
33%
Cell Death Pathways
33%
Skin Melanoma
33%
Cell Death Response
33%
Patient Survival Rate
33%
Anti-CTLA-4
33%
Anti-PD-1
33%
Trial Experimentation
33%
Mouse Melanoma Cells
33%
Medicine and Dentistry
Immunogenic Cell Death
100%
Calreticulin
100%
Melanoma
100%
Cancer
66%
Cell Membrane
33%
Surgery
33%
Early Diagnosis
33%
Clinical Trial
33%
Survival Rate
33%
Autoimmune Disease
33%
Melanoma Cell
33%
Immunity
33%
Pharmacology, Toxicology and Pharmaceutical Science
Melanoma
100%
Calreticulin
100%
Immunogenic Cell Death
100%
Clinical Trial
33%
Survival Rate
33%
Autoimmune Disease
33%
Cytotoxic T Lymphocyte Antigen 4
33%
Immunology and Microbiology
Cell Death
100%
Calreticulin
100%
Cell Membrane
33%
Autoimmune Disease
33%
Immunity
33%
Survival Rate
33%
Melanoma Cell
33%
Biochemistry, Genetics and Molecular Biology
Cell Death
100%
Calreticulin
100%
Cell Membrane
33%
Survival Rate
33%
Immunity
33%
Clinical Trial
33%